PP12 CD8 LEVELS IN PATIENTS WITH NSCLC UNDERGOING CHEMOTHERAPY IN MEDAN

Muhammad Faiz1, Setia Putra Tarigan1, Noni N. Soeroso1
Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia1

Introduction:

Lung tumours are the leading cause of cancer and death worldwide. Cell surface CD8-expressing cytotoxic T cells are the most potent effectors in anticancer immune responses and form the backbone of today's successful cancer immunotherapies. Immune checkpoint inhibitors are designed to target immune inhibitory receptors that function to regulate immune responses. In contrast, adoptive cell transfer therapy utilizes CD8+ T cells with genetically modified receptors - chimeric antigen receptors - to define and enhance CD8+ T cell functionality. New generations of cytotoxic T cells with genetically or synthetically modified receptors are being developed and evaluated in clinical trials.

Objectives:

Based on the background described above, a problem can be formulated in this study, namely, Cd8 Levels In Patients With NSCLC undergoing Chemotherapy In Medan City.

Methods:

This is a cross-sectional study using plasma serum extracted from a patient with NSCLC undergoing chemotherapy in Medan. The serums were checked in the USU laboratory using ELISA. The value is then analyzed using a Statistical Program (SPSS)

Results:

Based on the study's results, it is known that lung cancer patients in the city of Medan were found in as many as 20 cases, with the most types of lung carcinoma being adenocarcinoma, as many as 12 cases (60%), and the stage of NSCLC being the majority of the IVA stage, as many as 14 cases (70%). The minimum CD8 value level in 20 patients was 1,588, and the maximum CD8 value was 8.593, with a mean of 3.551.

Conclusions:

The level of CD8 in NSCLC patients can be used as an indication of immunity against cancer cell